Research Program Focus
Understanding the basic mechanisms of immunity to viral infections in mucosal tissues.
Research Program Statement
The Lund lab has an overarching interest in improving women’s health. Women are disproportionately affected by sexually transmitted infections. In general, women are more susceptible, experience more frequent and severe complications, including infertility, and yet women’s health is historically understudied. This lack of knowledge impairs our ability to design new therapeutic and prevention measures to treat or prevent infections and thereby limit the adverse health outcomes associated with these infections.
Thus, our goal is to learn how to better protect the female genital tract from invading viruses and bacteria. The lab does this by studying immune cells in the female genital tract to understand how to balance an effective immune response at this site of the body without leading to harmful inflammation that could cause damage to these tissues or jeopardize fertility. In recent years, immunologists have learned that immune cells behave and function differently in different areas of the body, so it is crucial to study genital tract immune cells to unlock new information about how to better guard this location from infection and diseases. We focus on furthering our understanding of basic mechanisms of anti-viral and mucosal immunity using both mouse models as well as human tissues.
Tissue resident memory T cell responses (TRM) are well known for their essential role in local tissue protection upon re-encounter with a pathogen. Notably, TRM can carry out direct anti-pathogen effector responses (via cytokines and cytolytic functions), while additionally playing an essential role in recruitment and activation of other arms of the tissue immune response through their sensing and alarm function. However, due to the ability of TRM to rapidly mount and potentiate a robust and broad tissue immune response upon pathogen re-encounter, we hypothesize that these cells must be tightly regulated to protect tissues from immune-mediated damage. We propose that this regulation and fine-tuning of the TRM response to re-infection is carried out at least in part by regulatory T cells (Treg).
The concept of tissue Tregs is well established and pioneering work has investigated these cells in nonlymphoid tissues including the muscle, visceral adipose tissue, and skin. This work has demonstrated that tissue Tregs have unique functions beyond their canonical immunosuppressive role dependent on their tissue niche, yet the features, fate, and role of tissue Tregs in context of infection, and particularly in tissue-based memory recall responses to infection, is not clear. Further, we lack an understanding of the signals that control Treg entry into and retention in the tissue in context of local infection, as well as the cues that guide their participation in the tissue recall response to infection. Here, we propose to define the features, fate, and mechanisms and consequences of action of Treg and tissue Treg in context of anti-viral tissue memory immune responses in mice and humans.
We hypothesize that tissue Tregs play critical roles during recall immune responses to infection in tissues via tuning local immunity to balance protection with restriction of immunopathology. We will address this question via three specific aims; in Aim 1, we will identify the features and fate of lymphoid tissue and mucosal memory Tregs in context of localized mucosal infections. In Aim 2, we will determine how Tregs in general and tissue Tregs specifically mediate tuning of the tissue-based T cell recall response to re-infection, focusing on both antigen-specific and bystander-activated T cell responses. In Aim 3, we will determine if Tregs limit viral-mediated disease through tuning the host immune response as well as through active tissue repair mechanisms. Together, these aims will define the mechanistic roles of tissue Tregs in shaping the tissue recall response to re-infection in mucosal tissues. The use of mouse and human tissues in the context of genital HSV-2 infection will enable us to make fundamental discoveries about memory and tissue Treg that are highly relevant to humans, while at the same time affording flexibility to investigate the mechanistic roles using the mouse model.
The Regulatory Role of Natural Progesterone in Barrier Immunity
The existence of biological sex-based differences in disease outcomes is well-established, but the underlying mechanisms are still poorly understood. Determining how the female sex hormone progesterone modulates immune responses and immune-associated pathologies has been particularly challenging. Progesterone is typically associated with restraining immune responses and reducing inflammation, with the expectation that this helps to induce immune tolerance for reproductive purposes. However, these previous findings could be at least in part due to the ability of certain forms of synthetic progesterone (including medroxyprogesterone acetate, which is sold under the name Depo Provera) to bind to the glucocorticoid receptor (GR). In contrast, the natural form of progesterone (pregn-4-ene-3,20-dione, or P4), which does not engage the GR, has been much less used in biological studies compared to synthetic progesterones. Here we propose to determine how P4 affects immunity in barrier tissues in steady-state conditions as well as during resolution of inflammation. We specifically focus on the effect of P4 on T cells with regulatory and inflammatory functions in the female reproductive tract using both primary human tissues and an animal model system. Importantly, our approach allows us to dissect direct and indirect effects of P4 on different components of the immune system, which is critical to understanding its mechanisms of action. Determining the effects of P4 is of urgent and utmost clinical relevance given the increasing clinical use of P4 across a wide range of diseases such as preventing the carcinogenic effects of post-menopausal estrogen replacement therapy, treating secondary amenorrhea, and preventing pre-term birth in high-risk pregnancies. Furthermore, our findings could help to provide a mechanistic framework for observed sex-based differences in autoimmunity and infectious disease outcomes.
Improving Vaccines to Protect against Mucosal Infections
Most licensed vaccines are administered via an intramuscular injection. This has proven to be highly effective for some infections, such as measles or HPV, where a single injection leads to long-lasting protective antibodies in the bloodstream that protect a person against infection for decades or even a lifetime. However, many infections lack effective vaccines, including HIV, herpes simplex virus, and tuberculosis, among others. There are many reasons for this, but one potential reason for vaccine failure is likely to be that candidate vaccines don’t induce immune responses at the infection entry point, which is generally a mucosal surface such as the lung, gastrointestinal tract, or genital tract. Most vaccine clinical trials measure antibodies in the bloodstream to determine if a vaccine induced immunity, but we predict that if you want to guard against infection, it is necessary to have immune cells present at the infection site, ready to protect the body at the first sign of infection. Our lab seeks to explore several different ways to generate and measure protective immune responses at sites where infections enter the body (such as the genital tract or the lungs) to improve vaccine-mediated protection. Specifically, our lab is working on vaccines against genital herpes virus (HSV-2), but we expect that lessons learned will be broadly applicable to other infections that pose a significant global health threat.
T-Cell Activation and Exhaustion in the HIV-Positive Female Genital Tract
HIV infection is a chronic viral infection that if untreated leads to progressive loss of the CD4 T cell compartment and eventually AIDS. In addition to loss of HIV-susceptible CD4 T cells, chronic HIV infection is characterized by robust systemic immune activation including B and T cell activation and proliferation and elevated levels of pro-inflammatory molecules. Indeed, the level of immune activation is strongly associated with HIV disease progression. Even upon antiretroviral therapy (ART) initiation and viral suppression, chronic HIV infection is associated with dysfunctional circulating immunity rather than a return to immune quiescence. Further, immune activation in mucosal compartments such as the gut can persist in chronically infected individuals, even with long-term ART. This chronic immune activation during HIV infection was first identified largely through study of men with HIV, though more recent studies have suggested that HIV-associated immune activation may manifest differently in women. Given that women are increasingly affected by HIV, with UNAIDS reporting that 53% of people living with HIV are women and girls as of 2020, it’s evident that there is a gap in our understanding of immune activation and dysfunction in women, particularly within the female genital tract (FGT) mucosa. A few initial studies have suggested that immune activation is elevated in the FGT of women with HIV, and that ART does not restore FGT immune status to homeostatic levels within the initial month of treatment. Thus, we propose to comprehensively evaluate immune activation and dysfunction in the FGT in settings of HIV infection with or without viral suppression for up to 24 months. In a well-characterized cohort of women with and without HIV infection in Mombasa, Kenya, we will test two primary hypotheses: 1) We hypothesize that HIV infection leads to increased immune activation in the FGT that persists after ART initiation and viral suppression, and 2) We hypothesize that that chronic and persistent HIV infection leads to exhaustion of mucosal tissue T cells within the FGT. We will advance the prior research by including a more thorough investigation of immune activation including a focus on regulatory T cell (Treg)-mediated immunoregulatory mechanisms, and T cell exhaustion through use of high-throughput single-cell analysis, and we will examine the effects of longer-term viral suppression on immune activation and dysfunction in both the circulation and FGT. This will allow us to better understand how HIV infection may lead to negative FGT health outcomes.
How do recurrent infections or exposures impact immune responses?
Among the many types of infections that pose significant global health challenges, there are many that cause repeat or recurrent infections. For example, an individual may have several flu or SARS- CoV-2 infections in their lifetime, or a person with herpes is likely to have many episodes of outbreaks throughout their lifespan. Our lab is interested in identifying why immunity is insufficient to protect against repeat or recurrent infections in these instances. We do this by studying how immune cells change with repeated infections using both mouse models as well as by studying humans with these infections. This work will help us to better understand the natural history of immune responses to repeat or recurrent infections so that we can improve upon nature to design efficacious therapies or prevention measures to limit repeat infections and associated disease.